Sofia Sandgren

Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Journal: JAMA neurology

Published: August 03, 2026

Propionic acid and neurofilament light chain in multiple sclerosis.

Propionic acid and neurofilament light chain in multiple sclerosis.

Journal: Brain : a journal of neurology

Published: May 21, 2026

Are neurofilament light chain levels ready for routine clinical use? - Yes.

Are neurofilament light chain levels ready for routine clinical use? - Yes.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: February 19, 2026

Diagnostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in Differentiating Primary From Serious Secondary Headache.

Diagnostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in Differentiating Primary From Serious Secondary Headache.

Journal: European journal of neurology

Published: December 25, 2025

Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls.

Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls.

Journal: Clinical chemistry and laboratory medicine

Published: November 08, 2025

Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity.

Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: November 05, 2025

Lymphocyte Dynamics and the Emergence of Secondary Autoimmunity Following Immune Reconstitution Therapies in Multiple Sclerosis.

Lymphocyte Dynamics and the Emergence of Secondary Autoimmunity Following Immune Reconstitution Therapies in Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: October 17, 2025

A novel multiplexed biomarker panel reveals key molecular pathways in progressive multiple sclerosis.

A novel multiplexed biomarker panel reveals key molecular pathways in progressive multiple sclerosis.

Journal: Brain communications

Published: October 02, 2025

Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response.

Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response.

Journal: Annals of clinical and translational neurology

Published: April 01, 2025

Quality of life is decreased in persons with relapsing-remitting multiple sclerosis experiencing progression independent of relapse activity.

Quality of life is decreased in persons with relapsing-remitting multiple sclerosis experiencing progression independent of relapse activity.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: February 18, 2025

The value of CSF diagnostic and prognostic biomarkers in NMOSD and MOGAD in real-life use.

The value of CSF diagnostic and prognostic biomarkers in NMOSD and MOGAD in real-life use.

Journal: Multiple sclerosis and related disorders

Published: October 30, 2024

Tyro3 and Gas6 are associated with white matter and myelin integrity in multiple sclerosis.

Tyro3 and Gas6 are associated with white matter and myelin integrity in multiple sclerosis.

Journal: Journal of neuroinflammation

Published: September 27, 2024

Showing 1-12 of 18

Last Updated: 09/26/2026